Increased levels of total tumor-infiltrating lymphocytes (TILs) are generally associated with
good prognosis in several breast cancer subtypes. Subtypes of TILs impact both tumor cells …

Triple-negative breast cancer (TNBC) is associated with high recurrence rates, high
incidence of distant metastases, and poor overall survival (OS). Taxane and anthracycline …

Despite remarkable clinical efficacy of immune checkpoint blockade (ICB) in cancer
treatment, ICB benefits for triple-negative breast cancer (TNBC) remain limited. Through …

Purpose: We recently reported the development of a cell-free DNA (cfDNA) targeted
methylation (TM)-based sequencing approach for a multi-cancer early detection (MCED) test …

Age and tumor subtype are prognostic factors for breast cancer survival, but it is unclear
which matters the most. We used population‐based data to address this question. We …

Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment
options. Mouse models of TNBC are important for development of new therapies, however …

Biomarkers can be used for diagnosis, prognosis, and prediction in targeted therapy. The
estrogen receptor α (ERα) and human epidermal growth factor receptor 2 (HER2) are …

Objective To describe stage I-III breast cancer (BC) molecular subtypes and outcomes
among a cohort of patients from Brazil. Methods AMAZONA study is a retrospective cohort …

Introduction: For decades, the role of glycans and glycoproteins in the progression of breast
cancer and other cancers have been evaluated. Through extensive studies focused on …

Background Triple negative breast cancer (TNBC) is an aggressive neoplasia with no
effective therapy. Our laboratory has developed a unique TNBC cell model presenting …